Treatment Patterns in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: Analysis of US Insurance Claims Databases.

ABSTRACT:

Background

Most patients with epidermal growth factor receptor mutation-positive (EGFRm) non-small-cell lung cancer (NSCLC) acquire resistance to first-line (1L) first- or second-generation (1G/2G) EGFR-TKIs; therefore, it is important to optimize 1L treatment to improve patient outcomes.

Objective

To retrospectively examine treatment patterns in locally advanced/metastatic NSCLC using MarketScan^® Commercial and Medicare Supplemental Databases (all US census regions).

Patients and methods

Adults with a lung cancer diagnosis code between 1 January 2015-31 March 2018 were analyzed from diagnosis (index) through a variable-length follow-up. Patients had ≥ 1 pharmacy claim for 1G/2G EGFR-TKIs on or within 60 days post-index. Data were stratified by presence or

SUBMITTER: Soo RA 

PROVIDER: S-EPMC8844326 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature